A Prospective, Efficacy Study of NuCel in Patients Undergoing Fusion for One, Two or Three Level Degenerative Disease of the Cervical Spine

Trial Profile

A Prospective, Efficacy Study of NuCel in Patients Undergoing Fusion for One, Two or Three Level Degenerative Disease of the Cervical Spine

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Amniotic cell therapy-NuCel (Primary)
  • Indications Intervertebral disc degeneration; Spinal stenosis; Spondylosis
  • Focus Therapeutic Use
  • Sponsors Nutech Medical
  • Most Recent Events

    • 19 Dec 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016.
    • 19 Dec 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Dec 2016.
    • 19 Dec 2016 Status changed from active, no longer recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top